IrelandIreland

Tibotec enters clinical collaboration with BMS in hepatitis C

05.12.2011

Dublin /New York – Irish Tibotec Pharmaceutical Ltd and Bristol-Myers Squibb (BMS) have entered into a clinical collaboration for the treatment of chronic hepatitis C infections with a combination of BMS’ NS5A replication complex blocker daclatasvir (BMS-790052) and Tibotec’s NS3 protease inhibitor, TMC435. The companies will evaluate the potential to achieve sustained viral response 12 and 24 weeks post treatment in patients with HCV genotype 1 in a study with three treatment regimens: an oral, once-daily treatment regimen of daclatasvir and TMC435 with pegylated-interferon alpha plus ribavirin; an oral, once-daily treatment regimen of daclatasvir and TMC435 with ribavirin and an oral, once-daily treatment regimen of daclatasvir and TMC435 alone. The Phase II study is planned to start in the first half of 2012.

IrelandIreland

14.10.2009

Dublin – Amarin Corporation plc today announced it has entered into an agreement with a number of investors for a $70 million private placement. The placement of units for $70 million consists of $66.4 million in cash proceeds...

IrelandIreland

19.09.2009

Dublin – The Republic of Ireland has amended its patent law to bring it into line with the rest of Europe and make its domestic patenting system more straightforward. The government said increased levels of research in Ireland in...

IrelandIreland

10.08.2009

Dublin - The honeymoon between Elan and Biogen has been over for a long time, now the marriage of the Irish biotech company and their US partner lies in ruins. The Elan Corporation has filed suit against Biogen Idec Inc. In the...

IrelandIreland

12.07.2009

Dublin – Ireland is focussing on expanding productivity in the upstream processing of biological drugs. Science Minister Conor Lenihan has announced EUR2.3m in funding for the next 3 years aimed at delivering more efficient and...

IrelandIreland

07.07.2009

Dublin/New Brunswick – Pharma giant Johnson &Johnson will buy all assets of Irish Elan Pharmaceuticals’ Alzheimer’s Immunotherapy Programme (AIP) through a newly formed company. The new company will pay $1 billion for an 18.4%...

IrelandIreland

17.06.2009

Dublin – Trinity College of Dublin's Institute of Molecular Medicine has opened Ireland´s first next generation DNA sequencing facility. The platform, built upon the current market-leading “Illumina Genome Analyzer II“ platform,...

IrelandIreland

14.06.2009

Dublin – Trinity College Dublin spin-out Opsona Therapeutics, a specialist in autoimmune and inflammatory diseases, has announced that the Roche Venture Fund and Enterprise Ireland have committed an additional EUR3.3m to the...

IrelandIreland

22.04.2009

Dublin – Ireland fears growing rates of resistant pneumococcus in the country's hospitals. A recent report by the Health Protection Surveillance Centre (HSPC) shows that 32% of 124 clinical isolates tested were non-susceptible to...

IrelandIreland

31.10.2008

Cork – Ireland is set to lose another 180 pharma jobs after pharmaceutical giant Pfizer announced it had failed to find a buyer for one of its five manufacturing facilities in the country. For the past 18 months, the company has...

IrelandIreland

14.08.2008

Dublin/Zurich – Analyst Ian Hunter of Goodbody Stockbrokers has maintained his “add” rating on Irish Elan Corp Plc. The fair value for the pharma combine has been raised from EUR18 to EUR19. The analyst says that the company has...

Displaying results 21 to 30 out of 49

< Previous 21-30 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-ireland/browse/2/article/tibotec-enters-clinical-collaboration-with-bms-in-hepatitis-c.html

Print Magazine

Product of the week

Products

Events

All Events

Current issue

All issues